QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.40 (-3.90%)
BABA   78.61 (-2.91%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.41%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.54%)
AMC   4.63 (-0.22%)
PFE   37.02 (-1.54%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)

Heron Therapeutics (HRTX) Stock Forecast, Price & News

$1.19
-0.09 (-7.03%)
(As of 05/30/2023 ET)
Compare
Today's Range
$1.15
$1.31
50-Day Range
$1.19
$2.88
52-Week Range
$1.07
$5.62
Volume
2.89 million shs
Average Volume
2.20 million shs
Market Capitalization
$142.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Heron Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
530.3% Upside
$7.50 Price Target
Short Interest
Bearish
18.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

576th out of 1,009 stocks

Pharmaceutical Preparations Industry

280th out of 494 stocks


HRTX stock logo

About Heron Therapeutics (NASDAQ:HRTX) Stock

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Heron Therapeutics (HRTX) Gets a Buy from Needham
Analyst Expectations for Heron Therapeutics's Future
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Earnings Preview: Heron Therapeutics
Why Shares of Heron Therapeutics Jumped Thursday
See More Headlines
Receive HRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HRTX Company Calendar

Last Earnings
3/23/2023
Today
5/30/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HRTX
Employees
302
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+541.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-182,020,000.00
Net Margins
-132.57%
Pretax Margin
-132.57%
Return on Equity
-21,127.62%

Debt

Sales & Book Value

Annual Sales
$107.67 million
Book Value
$0.11 per share

Miscellaneous

Free Float
113,705,000
Market Cap
$140.06 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Craig A. Collard
    Chief Executive Officer & Director
  • David L. Szekeres
    Chief Operating Officer & Executive Vice President
  • Thomas B. Ottoboni
    Chief Scientific Officer & SVP-Pharmaceutical
  • Chris M. Storgard
    Chief Medical Officer
  • Lisa Peraza
    Chief Accounting Officer & Vice President













HRTX Stock - Frequently Asked Questions

Should I buy or sell Heron Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings
or view top-rated stocks.

What is Heron Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $10.00. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 541.0% from the stock's current price.
View analysts price targets for HRTX
or view top-rated stocks among Wall Street analysts.

How have HRTX shares performed in 2023?

Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX stock has decreased by 53.2% and is now trading at $1.17.
View the best growth stocks for 2023 here
.

When is Heron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HRTX earnings forecast
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 21,127.62% and a negative net margin of 132.57%. The company's quarterly revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.54) EPS.

What ETFs hold Heron Therapeutics' stock?

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD), Simplify Propel Opportunities ETF (SURI) and Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), JPMorgan Chase & Co. (5.92%), Great Point Partners LLC (4.88%), Palisade Capital Management LP (3.33%), ArrowMark Colorado Holdings LLC (2.80%) and State Street Corp (2.14%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $1.17.

How much money does Heron Therapeutics make?

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $140.06 million and generates $107.67 million in revenue each year. The biotechnology company earns $-182,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Heron Therapeutics have?

The company employs 302 workers across the globe.

Does Heron Therapeutics have any subsidiaries?
The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..
Read More
How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.

This page (NASDAQ:HRTX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -